Your browser doesn't support javascript.
Prognostic implications of myocardial injury in patients with and without COVID-19 infection treated in a university hospital.
Bardají, Alfredo; Carrasquer, Anna; Sánchez-Giménez, Raúl; Lal-Trehan, Nisha; Del-Moral-Ronda, Víctor; Peiró, Óscar M; Bonet, Gil; Castilho, Gislaine; Fort-Gallifa, Isabel; Benavent, Clara; Recio, Gemma; Gutiérrez, Cristina; Villavicencio, Christian; Auguet, Teresa; Boqué, Carme.
  • Bardají A; Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain; Universidad Rovira Virgili, Tarragona, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain. Electronic address: abardaji.hj23.ics@gencat.cat.
  • Carrasquer A; Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain; Universidad Rovira Virgili, Tarragona, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.
  • Sánchez-Giménez R; Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain.
  • Lal-Trehan N; Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain.
  • Del-Moral-Ronda V; Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain.
  • Peiró ÓM; Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain.
  • Bonet G; Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain.
  • Castilho G; Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.
  • Fort-Gallifa I; Laboratori Clínic ICS Camp de Tarragona-Terres de l'Ebre, Instituto Catalán de la Salud, Tarragona, Spain.
  • Benavent C; Laboratori Clínic ICS Camp de Tarragona-Terres de l'Ebre, Instituto Catalán de la Salud, Tarragona, Spain.
  • Recio G; Laboratori Clínic ICS Camp de Tarragona-Terres de l'Ebre, Instituto Catalán de la Salud, Tarragona, Spain.
  • Gutiérrez C; Laboratori Clínic ICS Camp de Tarragona-Terres de l'Ebre, Instituto Catalán de la Salud, Tarragona, Spain.
  • Villavicencio C; Servicio de Cuidados Intensivos, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain.
  • Auguet T; Universidad Rovira Virgili, Tarragona, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Servicio de Medicina Interna, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain.
  • Boqué C; Universidad Rovira Virgili, Tarragona, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Servicio de Urgencias, Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain.
Rev Esp Cardiol (Engl Ed) ; 74(1): 24-32, 2021 Jan.
Article in English, Spanish | MEDLINE | ID: covidwho-989111
ABSTRACT
INTRODUCTION AND

OBJECTIVES:

Cardiac troponin, a marker of myocardial injury, is frequently observed in patients with COVID-19 infection. Our objective was to analyze myocardial injury and its prognostic implications in patients with and without COVID-19 infection treated in the same period of time.

METHODS:

The present study included patients treated in a university hospital with cardiac troponin I measurements and with suspected COVID-19 infection, confirmed or ruled out by polymerase chain reaction analysis. The impact was analyzed of cardiac troponin I positivity on 30-day mortality.

RESULTS:

In total, 433 patients were distributed among the following groups confirmed COVID-19 (n=186), 22% with myocardial injury (n=41); and ruled out COVID-19 (n=247), 21.5% with myocardial injury (n=52). The confirmed and ruled out COVID-19 groups had a similar age, sex, and cardiovascular history. Mortality was significantly higher in the confirmed COVID-19 group than in the ruled out group (19.9% vs 5.3%, P <.001). In Cox multivariate regression analysis, cardiac troponin I was a predictor of mortality in both groups (confirmed COVID-19 group HR, 3.54; 95%CI, 1.70-7.34; P=.001; ruled out COVID-19 group HR, 5.57; 95%CI, 1.70-18.20; P=.004). The predictive model analyzed by ROC curves was similar in the 2 groups (P=.701), with AUCs of 0.808 in the confirmed COVID-19 group (0.750-0.865) and 0.812 in the ruled out COVID-19 group (0.760-0.864).

CONCLUSIONS:

Myocardial injury is detected in 1 in every 5 patients with confirmed or ruled out COVID-19 and predicts 30-day mortality to a similar extent in both circumstances.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Troponin I / SARS-CoV-2 / COVID-19 / Cardiomyopathies Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English / Spanish Journal: Rev Esp Cardiol (Engl Ed) Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Troponin I / SARS-CoV-2 / COVID-19 / Cardiomyopathies Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English / Spanish Journal: Rev Esp Cardiol (Engl Ed) Year: 2021 Document Type: Article